Pharmaceutical intervention in the JAK/STAT signaling pathway.
about
JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expressionMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaThymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3The effect of erythropoietin on normal and neoplastic cells.STAT proteins: novel molecular targets for cancer drug discovery.A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activationMeasles contributes to rheumatoid arthritis: evidence from pathway and network analyses of genome-wide association studies.Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acidIL-20: a new target for the treatment of inflammatory skin disease.Roles and regulation of stat family transcription factors in human breast cancer.The ins and outs of STAT1 nuclear transport.JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Treatment of neurodegenerative diseases using adult bone marrow stromal cell-derived neurons.Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.PPAR Regulation of Inflammatory Signaling in CNS Diseases.Current status and challenges of cytokine pharmacology.Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B.The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines.Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma.Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway.St. John's wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors.Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition.Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand.gamma-Glutamyl transpeptidase expression in Ewing's sarcoma cells: up-regulation by interferons.Signaling pathways regulating interleukin-13-stimulated chemokine release from airway smooth muscle.Inhibition of matrix metalloproteinase-9 by interferons and TGF-beta1 through distinct signalings accounts for reduced monocyte invasiveness.
P2860
Q24316553-1083FBEF-498D-491E-8523-0C06CEFC4CECQ26774636-EDBCE3AB-D43B-42C9-BDA1-4D0C1D35AB4CQ28069864-FC33E8E6-7C7D-46DC-A2A0-BDD592BD032FQ34046503-D71D3FA4-7DAE-4CE6-B407-5D83EC771C21Q34291437-E1550826-B087-4267-B6E1-16ADA7E8BEE8Q34293579-44FF4C4E-5E4C-4946-8FDA-0056A64F9A76Q34356962-F5BE6FAC-B3D1-4EFA-9849-82277922627DQ35034525-C1A9B869-27AD-4472-9E51-EE1A4294F6EDQ35044752-0F0C3AC9-6818-4E36-83E6-D62CF353969AQ35095128-F4051F13-06BE-4E62-B505-36BAFDBBC9C6Q35103357-4A392ED0-BD14-46F9-864C-28D22943B9CAQ35198415-EF9F1E63-B808-4FB3-9DCD-BC3681E38A5EQ35214530-7E4A49F4-6948-4D2B-A9F7-8422079E2C73Q35858979-359D9707-FFBB-4FA4-934B-52CB991EF8FCQ36150397-2278000D-A825-4E47-9465-4DA5A9C7928CQ36801561-EE07CCCC-867B-4CF2-B1EF-12D5A895C626Q37231755-62764B62-70FD-4D92-B0E7-BC9EBA4B50E0Q37445966-BB074D7B-83C4-4232-94AC-E2040565F874Q38287385-A85DEE1E-D4C8-4371-AD5B-D34A601085C0Q38349780-521A73FD-D5BA-4551-903D-356F9A6C2A09Q38757788-38261BE2-1E5F-4F57-8734-A6E4DE84F79AQ38974299-467DA3AA-D865-4152-839E-520975FBC050Q39079749-3FE0AEF7-3A78-4A92-919C-830AB09B5F4FQ39204274-A2E5C051-68CB-49CA-8D55-6DCBEC448A3BQ39928103-C6D9BE8E-DE64-4E74-A520-607CAA11AC7EQ40290658-BE9C07E7-DD10-4B5D-8BF5-53434F35B550Q40504454-C8B33B0B-BF34-431E-9643-B6E59312255CQ40678280-655B80C9-F0A8-48DD-9411-9BB9D5E8A53BQ40727451-DA260F77-69E0-4296-A784-6ACD716ECAEBQ44689962-823479B8-A44C-4FDC-85D1-1094943DCE83Q46742743-539A1CFE-584D-4D41-BE4A-C4590C69E0D2
P2860
Pharmaceutical intervention in the JAK/STAT signaling pathway.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@ast
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@en
type
label
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@ast
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@en
prefLabel
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@ast
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@en
P2093
P2860
P356
P1433
P1476
Pharmaceutical intervention in the JAK/STAT signaling pathway.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203550
P407
P577
2000-05-01T00:00:00Z
P5875
P6179
1021904486